Substances analysed by GCMS and LCMS in Sore+Tired BLUE™ Magnesium Sulfate Formula Hydrogel

Substances analysed by GCMS	Method Capability*		Reporting Level*		Cleared (ie: none detected)
	Standard Test	Fats/Oils Test[4]	Standard Test	Fats/Oils Test[4]	√
1,4-androstadiene-3,17-dione	10 ng/g	50 ng/g	10 ng/g[2]	50 ng/g[2]	√
4-androstene-3,17-dione and/or 5(6)-androstene-3,17-dione[1]	-	-	20 ng/g (50 ng/g)[3]	50 ng/g	√
4-androstene-3β,17β-diol	-	-	20 ng/g	50 ng/g	√
5α-androstane-3β,17β-diol	-	-	20 ng/g	50 ng/g	√
5(6)-androstene-3β,17β-diol	-	-	20 ng/g	50 ng/g	√
5α-androstane-3,17-dione	-	-	20 ng/g	50 ng/g	√
Dehydroepiandrosterone (DHEA)	-	-	20 ng/g	50 ng/g	√
4-estrene-3,17-dione(19-nor-4-androstene-3,17-dione) and/or 5(10)-estrene-3,17-dione (19-nor-5(10)-androstene-3,17-dione) and/or 5(6)-estrene-3,17-dione (19-nor-5(6)-androstene-3,17-dione) [1]	10 ng/g	50 ng/g	-	-	√
4-estrene-3β,17β-diol (19-nor-4-androstene-3β,17β-diol) and/or 5(10)-estrene-3β,17β-diol (19-nor-5(10)-androstene-3β,17β-diol) [1]	10 ng/g	50 ng/g	-	-	√
Nandrolone (19-nor-4-androstene-17β-hydroxy-3-one)	10 ng/g	50 ng/g	-	-	√
Testosterone	-	-	20 ng/g	50 ng/g	√

* See section 1.1 for full definitions of terms.

1 These compounds are isomeric and indistinguishable from each other by this test.
2 Reporting level applies to supplements containing botanical ingrediants only.
3 Reporting level of 50ng/g applicable to products containing milk or milk derived substances (see additional note relating to "Androstenedione in milk and milk based products").
4 Method capability / reporting levels only applicable to oil based products

Substances analysed by LCMS	Method Capability*	Reporting Level*	Cleared (ie: none detected)
1(3-chlorophenyl)piperazine	100 ng/g	-	√
1,3-dimethylbutylamine	100 ng/g	-	√
20-Norstanozolol	10 ng/g	-	√
7-ketoDHEA	500 ng/g	-	√
α-ethylphenethylamine	100 ng/g	-	√
Acebutolol	100 ng/g	-	√
Alfentanil	100 ng/g	-	√
Alprenolol	100 ng/g	-	√
Amiloride	500 ng/g	-	√
Amiphenazole	100 ng/g	-	√
Amphetamine	100 ng/g	-	√
Atenolol	100 ng/g	-	√
β-methylphenethylamine	100 ng/g	-	√
Bambuterol	100 ng/g	-	√
Benzoylecgonine	100 ng/g	-	√
Benzphetamine	100 ng/g	-	√
Benzylpiperazine	100 ng/g	-	√
Bisoprolol	100 ng/g	-	√
Bumetanide	100 ng/g	-	√
Bunitrolol	100 ng/g	-	√
Bupranolol	100 ng/g	-	√
Buprenorphine	100 ng/g	-	√
Bupropion	100 ng/g	-	√
Butofinolol	100 ng/g	-	√
Canrenone	100 ng/g	-	√
Carazolol	100 ng/g	-	√
Carfentanil	100 ng/g	-	√
Carphedone	100 ng/g	-	√
Carteolol	100 ng/g	-	√
Celiprolol	100 ng/g	-	√

Substances analysed by LCMS	Method Capability*	Reporting Level*	Cleared (ie: none detected)
Chlorphentermine	100 ng/g	-	√
Cimaterol	100 ng/g	-	√
Clenbuterol	10 ng/g	-	√
Clomifene	100 ng/g	-	√
Clopamide	100 ng/g	-	√
Clobenzorex	100 ng/g	-	√
Clorprenaline	100 ng/g	-	√
Cocaine	100 ng/g	-	√
Croethamide	100 ng/g	-	√
Cyclopentamine	100 ng/g	-	√
Cyproheptadine	100 ng/g	-	√
Dextromoramide	100 ng/g	-	√
Diamorphine	100 ng/g	-	√
Diethylpropion	100 ng/g	-	√
Dimethamphetamine	100 ng/g	-	√
Dipipanone	100 ng/g	-	√
Diprenorphine	100 ng/g	-	√
Doxapram	100 ng/g	-	√
Ephedrine / Pseudoephedrine	-	100 ng/g	√
Esmolol	100 ng/g	-	√
Etafedrine	100 ng/g	-	√
Etamivan	100 ng/g	-	√
Fenbutrazate	100 ng/g	-	√
Fencamfamine	100 ng/g	-	√
Fenfluramine	100 ng/g	-	√
Fenoterol	100 ng/g	-	√
Fenozolone	100 ng/g	-	√
Fentanyl	100 ng/g	-	√
Fluorophenethylamine	100 ng/g	-	√
Fluoxetine	100 ng/g	-	√
Fluvoxamine	100 ng/g	-	√

Substances analysed by LCMS	Method Capability*	Reporting Level*	Cleared (ie: none detected)
Formoterol	100 ng/g	-	√
Gestrinone	10 ng/g	-	√
Heptaminol	100 ng/g	-	√
HMMA	100 ng/g	-	√
Indapamide	100 ng/g	-	√
Isometheptene	100 ng/g	-	√
Labetolol	100 ng/g	-	√
Levophacetoperane	100 ng/g	-	√
Mabuterol	100 ng/g	-	√
MDEA	100 ng/g	-	√
MDA	100 ng/g	-	√
MDMA (ecstasy)	100 ng/g	-	√
Mefenorex	100 ng/g	-	√
Mefruside	100 ng/g	-	√
Mephentermine	100 ng/g	-	√
Methadone	100 ng/g	-	√
Methamphetamine	100 ng/g	-	√
Methoxyphenylpiperazine	100 ng/g	-	√
Methylephedrine	100 ng/g	-	√
Methylhexanamine (1,3-dimethylamylamine)	100 ng/g	-	√
Methylphenidate	100 ng/g	-	√
Methylpseudoephedrine	100 ng/g	-	√
Methyltrienolone	100 ng/g	-	√
Metoprolol	100 ng/g	-	√
Modafinil	100 ng/g	-	√
Moprolol	100 ng/g	-	√
N,α-diethylphenethylamine	100 ng/g	-	√
N,β-dimethylphenethylamine	100 ng/g	-	√
Nadolol	100 ng/g	-	√
Nadoxolol	100 ng/g	-	√
Nalbuphine	100 ng/g	-	√

Substances analysed by LCMS	Method Capability*	Reporting Level*	Cleared (ie: none detected)
Nalorphine	100 ng/g	-	√
Naloxone	100 ng/g	-	√
Naltrexone	100 ng/g	-	√
Nikethamide	100 ng/g	-	√
Norephedrine	100 ng/g	-	√
Norpseudoephedrine (Cathine)	100 ng/g	-	√
Oripavine	100 ng/g	-	√
Oxilofrine	100 ng/g	-	√
Oxprenolol	100 ng/g	-	√
Oxycodone	100 ng/g	-	√
Oxymetazoline	100 ng/g	-	√
Pemoline	100 ng/g	-	√
Penbutolol	100 ng/g	-	√
Pentazocine	100 ng/g	-	√
Pentoxyverine	100 ng/g	-	√
Pethidine	100 ng/g	-	√
Phendimetrazine	100 ng/g	-	√
Phenmetrazine	100 ng/g	-	√
Phentermine	100 ng/g	-	√
Pindolol	100 ng/g	-	√
Pirbuterol	100 ng/g	-	√
Piretanide	100 ng/g	-	√
Polythiazide	100 ng/g	-	√
Practolol	100 ng/g	-	√
Probenecid	100 ng/g	-	√
Prolintane	100 ng/g	-	√
Propranolol	100 ng/g	-	√
Prostanozol	10 ng/g	-	√
Prothipendyl	100 ng/g	-	√
Quinethazone	100 ng/g	-	√
Ritodrine	100 ng/g	-	√

Substances analysed by LCMS	Method Capability*	Reporting Level*	Cleared (ie: none detected)
Salbutamol	100 ng/g	-	√
Salmeterol	100 ng/g	-	√
Selegiline	100 ng/g	-	√
Sibutramine	100 ng/g	-	√
Sildenafil	100 ng/g	-	√
Sotalol	100 ng/g	-	√
Spironolactone	100 ng/g	-	√
Stanozolol	10 ng/g	-	√
Strychnine	100 ng/g	-	√
Tamoxifen	100 ng/g	-	√
Terbutaline	100 ng/g	-	√
Tetrahydrogestrinone (THG)	10 ng/g	-	√
Timolol	100 ng/g	-	√
Torasemide	100 ng/g	-	√
Toremifene	100 ng/g	-	√
Trenbolone	100 ng/g	-	√
Triamterene	100 ng/g	-	√
Trifluoromethylphenylpiperazine	100 ng/g	-	√
Tripamide	100 ng/g	-	√
Tuaminoheptane	100 ng/g	-	√
Tulobuterol	100 ng/g	-	√
Xylomatazoline	100 ng/g	-	√

* See section 1.1 for full definitions of terms.

Technical Description of Service

- Each sample was tested for the presence of the compounds listed above at the Method Capability / Reporting Levels indicated (definitions provided in section 1.1 below).
- Sample preparation was by liquid and solid phase extraction techniques.
- Internal marker(s) were added to each sample to assess suitability of matrix for testing.
- Positive and negative controls were analysed alongside samples to assess extraction efficiency.
- Analysis was conducted using gas chromatography with mass spectrometric detection (GCMS) and liquid chromatography with mass spectrometric detection (LCMS).
- A Laboratory Information Management System (LIMS) was used to record sample details and analysis findings.
- The test results were qualitative and only apply to the sub-sample of the batch that was received

at the laboratory for testing. However, the tests applied to the sub-sample are highly sensitive and, assuming batch homogeneity, the results obtained are intended to provide an assessment of potential batch contamination as a whole.

- The range of substances included in the testing protocol were based on current knowledge and intelligence, and updated as necessary.

1.1 Testing Procedure

The testing process included the analysis of positive and negative control samples alongside each batch of test samples. The analytical data from the test sample(s) were compared directly with the data from the control samples.

The positive control samples contain the test substances (or representative isomers) at the validated method capability / reporting levels for each procedure (see definitions provided below).

1.1.a Method Capability:

Method capability levels for each substance (where appropriate) are specified in preceding table. Samples were reported as a screening indication for a particular substance if screening tests and verification analysis meets established acceptance criteria. The method capability level represents a level at which the substances can be successfully detected within a wide variety of matrices. It should be noted that within certain matrices, levels lower than those specified may be reported as a screening indication if all acceptance criteria are met.

1.1.b Reporting Level:

Reporting levels for each substance (where appropriate) are specified within the preceding table. Samples were reported as a screening indication for a particular substance if the test indicated its presence at or above the reporting level specified. Results from the test sample were compared to a control sample to determine whether a drug was present at, above or below the specified concentration.

1.2 Androstenedione in milk and milk based products

Androstenedione is known to be naturally present in milk and milk derived products so this analysis was not deemed relevant for Sore+Tired products.

1.3 Oil based products (e.g. fish / plant oil)

Oil based products were analysed at an increased method capability / reporting level for the test substances analysed by GCMS, as indicated the preceding table.

1.4 1,-4-androstadiene-3,17-dione in supplements containing botanical ingredients.

A reporting level of 10ng/g was applied based on the presence of botanical or botanical derived ingredients (noting the potential biotransformation of plant sterols into 1,4-androstadiene-3,17-dione).

ACCREDITED
Certificate # 3244.01

LGC Science, Inc.
1745 Alysheba Way
Suite 160
Lexington, KY 40509

Tel: 859-721-0180
Fax: 859-264-0371

Michael McLinden
Miscopeto, LLC
410 Main St
Winchester, MA 01890
USA

Date Issued: June 28, 2018

CERTIFICATE OF ANALYSIS: 26831

LGC Supplement Screen

Consignment Number:	9500112445328163179836 USPS
Delivery Date:	June 19, 2018
Date Analysis Commenced:	June 19, 2018
Purchase Order Number:	N/A

Product:	Sore + Tired BLUE		
Flavor:			
Batch No:	Batch 1 2018	**Screen Type:**	Supplement Screen
Batch Expiry:		**LGC Reference:**	361125

The sample was analyzed using documented ISO17025 accredited LGC screening methods for the compounds specified within the Testing Specification: Nutritional Supplements V1.

GCMS:
None were found

LCMS:
None were found

Signed
Lily Styles
Senior Scientist

Test results apply to the portion of product taken.
* or isomers of - as specified within the service level agreement.